文献速递膀胱癌与上尿路尿路上皮癌

伴发原位癌分布对非肌层浸润性膀胱癌进展风险的影响

Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
PubMed 文献 · BJU Int · 2025-05-26

这项多机构回顾性队列研究纳入2005至2022年治疗的2923例pTa/pT1非肌层浸润性膀胱癌(NMIBC)患者,评估伴发原位癌(CIS)为单灶还是多灶对进展风险的影响。中位随访5.1年,383例(13%)进展,327例(11%)伴发CIS,其中233例为单灶、94例为多灶。调整混杂因素后,仅多灶伴发CIS与进展风险独立相关(sHR 1.90,95%CI 1.18-3.05,P=0.008),单灶CIS并非独立危险因素。

要点

  • 伴发CIS的NMIBC患者中,仅多灶CIS与进展风险升高独立相关。
  • 单灶伴发CIS未显示为T1期NMIBC进展的独立危险因素。
  • 经尿道切除时按指南建议分送标本,有助于区分CIS分布。

核心结论

  • 乳头状NMIBC的进展风险随伴发CIS的分布而异。
  • 仅多灶伴发CIS是T1期NMIBC患者的进展危险因素。
  • 若经进一步研究验证,风险计算器应考虑纳入CIS分布这一区分。

研究设计与样本

  • 多机构回顾性队列研究,纳入学术与社区医院2005至2022年治疗的pTa/pT1 NMIBC患者。
  • 共纳入2923例患者,中位随访5.1年(四分位距3.0-8.5年)。
  • 单灶伴发CIS定义为仅一个标本存在CIS,多灶伴发CIS定义为多个标本存在CIS。
  • 进展定义为发生肌层浸润性疾病或转移性疾病。
  • 采用Fine-Gray回归分析进展相关因素,以全因死亡作为竞争风险。

主要发现

  • 2923例中383例(13%)出现进展。
  • 327例(11%)伴发CIS,其中233例为单灶、94例为多灶。
  • 复发肿瘤、T1期、高级别、多灶CIS和多发肿瘤均与进展风险升高独立相关(均P<0.05)。
  • 在伴发CIS患者中,调整年龄、性别、肿瘤史、分期、分级、肿瘤数目、肿瘤直径和卡介苗治疗后,多灶CIS仍为显著预后因素(sHR 1.90,95%CI 1.18-3.05,P=0.008)。

关键数值与推荐

  • 伴发CIS患者中多灶CIS的亚分布风险比为1.90(95%CI 1.18-3.05,P=0.008)。
  • 进展相关因素包括复发肿瘤、T1期、高级别、多灶CIS和多发肿瘤(均P<0.05)。
  • 单灶伴发CIS在T1期NMIBC中未显示为独立进展危险因素。

临床怎么用

  • 评估乳头状NMIBC进展风险时,应区分伴发CIS为单灶还是多灶。
  • 对多灶伴发CIS患者应给予更密切的随访与风险分层管理。
  • 经尿道切除时应按指南建议分送标本,以利于判断CIS分布。

局限性

  • 为回顾性队列研究,存在回顾性设计固有偏倚。
  • CIS分布区分纳入风险计算器尚需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether the distribution of concomitant carcinoma in situ (CIS; unifocal or multifocal) with papillary non-muscle-invasive bladder cancer (NMIBC) impacts the risk of progression, as concomitant CIS is an established risk factor for progression in papillary NMIBC and commonly used calculators do not make this distinction. PATIENTS AND METHODS: In this multi-institutional retrospective cohort study from both academic and community hospitals, clinicopathological data were collected from patients with pTa/pT1 NMIBC treated from 2005 to 2022. Unifocal concomitant CIS was defined as CIS present in only one specimen (i.e., papillary disease with CIS at the tumour base or isolated CIS in one specimen). Multifocal concomitant CIS was characterised by CIS in multiple specimens. Progression was defined as the development of muscle-invasive or metastatic disease. Fine-Gray regression was performed to identify progression-associated factors, using all-cause mortality as a competing risk. RESULTS: Among 2923 patients, 383 (13%) progressed over a median (interquartile range) follow-up of 5.1 (3.0-8.5) years. Concomitant CIS was found in 327 patients (11%), with 233 and 94 harbouring unifocal and multifocal CIS, respectively. Recurrent tumours, T1 stage, high-grade disease, multifocal CIS, and multiple tumours were independently associated with increased progression risk (all P < 0.05). Among patients with concomitant CIS, multifocal CIS remained a significant prognosticator (sub-distribution hazard ratio 1.90, 95% confidence interval 1.18-3.05; P = 0.008) adjusting for age, sex, tumour history, stage, grade, number of tumours, tumour diameter, and Bacillus Calmette-Guérin treatment. CONCLUSIONS: Papillary NMIBC progression risk varies with concomitant CIS distribution. Only multifocal concomitant CIS is a risk factor for progression in patients with T1 NMIBC. If validated in further studies, risk calculators should consider including this CIS distinction. Submitting separate specimens at the time of transurethral resection, as recommended by guidelines, should be encouraged.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kwong JCC, Pace K, Al-Daqqaq Z, et al. Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk. BJU Int. 2025. PMID: 40415640. doi:10.1111/bju.16793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。